Effect of hemodialysis on total antioxidant capacity and serum antioxidants in patients with chronic renal failure. 1995

P Jackson, and C M Loughrey, and J H Lightbody, and P T McNamee, and I S Young
Department of Clinical Biochemistry, Queen's University of Belfast, Northern Ireland.

Cardiovascular disease is the major cause of mortality in patients receiving hemodialysis for chronic renal failure. Increased lipid peroxidation and depletion of chain-breaking antioxidants may contribute to increased risk of atherosclerosis. We have therefore assessed the effect of a single episode of hemodialysis on antioxidant status in 22 patients and control subjects. Overall, total antioxidant capacity of serum was increased in dialysis patients, but there was a marked reduction after hemodialysis [571 +/- 31 vs 342 +/- 22 mumol/L Trolox (water-soluble vitamin E analog) equivalents, P < 0.001]. The increase in total antioxidant capacity before hemodialysis was almost entirely due to relatively high serum urate. Among individual chain-breaking antioxidants, dialysis led to a decrease in urate (398 +/- 15 vs 136 +/- 12 mumol/L, P < 0.001), ascorbate (10.5 +/- 1.7 vs 5.9 +/- 1.0 mumol/L, P < 0.01), and lipid-corrected tocopherol (4.70 +/- 0.56 vs 4.26 +/- 0.39 mumol/mmol cholesterol, P < 0.05). Protein thiol groups increased after dialysis (328 +/- 16 vs 422 +/- 22 mumol/L, P < 0.001), whereas albumin remained unchanged (40.1 +/- 1.1 vs 41.0 +/- 1.6 g/L, not significant). Although total antioxidant capacity of serum is increased in hemodialysis patients, depletion of key chain-breaking antioxidants may lead to accelerated atherogenesis.

UI MeSH Term Description Entries
D007676 Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION. ESRD,End-Stage Renal Disease,Renal Disease, End-Stage,Renal Failure, Chronic,Renal Failure, End-Stage,Chronic Kidney Failure,End-Stage Kidney Disease,Chronic Renal Failure,Disease, End-Stage Kidney,Disease, End-Stage Renal,End Stage Kidney Disease,End Stage Renal Disease,End-Stage Renal Failure,Kidney Disease, End-Stage,Renal Disease, End Stage,Renal Failure, End Stage
D008297 Male Males
D008315 Malondialdehyde The dialdehyde of malonic acid. Malonaldehyde,Propanedial,Malonylaldehyde,Malonyldialdehyde,Sodium Malondialdehyde,Malondialdehyde, Sodium
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D001798 Blood Proteins Proteins that are present in blood serum, including SERUM ALBUMIN; BLOOD COAGULATION FACTORS; and many other types of proteins. Blood Protein,Plasma Protein,Plasma Proteins,Serum Protein,Serum Proteins,Protein, Blood,Protein, Plasma,Protein, Serum,Proteins, Blood,Proteins, Plasma,Proteins, Serum
D002784 Cholesterol The principal sterol of all higher animals, distributed in body tissues, especially the brain and spinal cord, and in animal fats and oils. Epicholesterol
D005260 Female Females
D006435 Renal Dialysis Therapy for the insufficient cleansing of the BLOOD by the kidneys based on dialysis and including hemodialysis, PERITONEAL DIALYSIS, and HEMODIAFILTRATION. Dialysis, Extracorporeal,Dialysis, Renal,Extracorporeal Dialysis,Hemodialysis,Dialyses, Extracorporeal,Dialyses, Renal,Extracorporeal Dialyses,Hemodialyses,Renal Dialyses
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

P Jackson, and C M Loughrey, and J H Lightbody, and P T McNamee, and I S Young
February 1980, Polskie Archiwum Medycyny Wewnetrznej,
P Jackson, and C M Loughrey, and J H Lightbody, and P T McNamee, and I S Young
November 1992, Metabolism: clinical and experimental,
P Jackson, and C M Loughrey, and J H Lightbody, and P T McNamee, and I S Young
January 1995, Romanian journal of internal medicine = Revue roumaine de medecine interne,
P Jackson, and C M Loughrey, and J H Lightbody, and P T McNamee, and I S Young
January 2011, Nigerian journal of clinical practice,
P Jackson, and C M Loughrey, and J H Lightbody, and P T McNamee, and I S Young
January 2017, Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia,
P Jackson, and C M Loughrey, and J H Lightbody, and P T McNamee, and I S Young
July 2015, Nephro-urology monthly,
P Jackson, and C M Loughrey, and J H Lightbody, and P T McNamee, and I S Young
January 1974, Gynecologic investigation,
P Jackson, and C M Loughrey, and J H Lightbody, and P T McNamee, and I S Young
January 2022, Journal of healthcare engineering,
P Jackson, and C M Loughrey, and J H Lightbody, and P T McNamee, and I S Young
December 1987, Wiadomosci lekarskie (Warsaw, Poland : 1960),
P Jackson, and C M Loughrey, and J H Lightbody, and P T McNamee, and I S Young
May 1999, Clinical nephrology,
Copied contents to your clipboard!